MwanzoMOR • ETR
add
MorphoSys AG
Bei iliyotangulia
€ 67.65
Bei za siku
€ 67.65 - € 68.00
Bei za mwaka
€ 14.52 - € 69.75
Thamani ya kampuni katika soko
2.55B EUR
Wastani wa hisa zilizouzwa
elfu 66.52
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
ETR
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 27.54M | 13.11% |
Matumizi ya uendeshaji wa biashara | 289.14M | 264.02% |
Mapato halisi | -314.96M | -608.87% |
Kiwango cha faida halisi | elfu -1.14 | -526.67% |
Mapato kwa kila hisa | -8.27 | -529.19% |
EBITDA | -263.38M | -388.32% |
Asilimia ya kodi ya mapato | 0.51% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 630.77M | -20.30% |
Jumla ya mali | 1.83B | -17.85% |
Jumla ya dhima | 2.09B | -1.84% |
Jumla ya hisa | -261.67M | — |
hisa zilizosalia | 37.62M | — |
Uwiano wa bei na thamani | -9.72 | — |
Faida inayotokana na mali | -34.27% | — |
Faida inayotokana mtaji | -41.11% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -314.96M | -608.87% |
Pesa kutokana na shughuli | -71.53M | 14.27% |
Pesa kutokana na uwekezaji | 28.62M | 187.62% |
Pesa kutokana na ufadhili | elfu -950.28 | 97.86% |
Mabadiliko halisi ya pesa taslimu | -27.24M | 75.37% |
Mtiririko huru wa pesa | 246.91M | 1,523.66% |
Kuhusu
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1992
Makao Makuu
Tovuti
Wafanyakazi
464
